Tag: Brain Penetration
-
OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration
LONDON, Oct. 7, 2026 /PRNewswire/ — OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product’s potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetrati…
Latest News
About the Author
Publicize Your Brand
Through our news networks, we raise millions of users’ awareness. We are among the world’s most reputable news networks.
